Immunome Research

Immunome Research
Open Access

ISSN: 1745-7580

+44-77-2385-9429

Abstract

Colon Cancer.

Stacy M*

High risk stage II colon cancer (CC) patients who will benefit from adjuvant treatment remains a clinical concern; however, no ideal model has been applied to clearly identify which suitable stage II CC patients should receive adjuvant chemotherapy. A previous study has provided an ideal and quantifiable model to identify suitable high risk stage II CC patients who should receive adjuvant chemotherapy after undergoing non-emergent surgery. This study is of importance; however, more factors should be taken into considerations to modify the prognostic model, which still requires further validation.

Top